Nuvalent ALKOVE-1 Data Boosts NSCLC Targeted Therapy
Cambridge, Massachusetts, USA, April 21, 2026 In a major advancement for targeted cancer therapy, Nuvalent, Inc. has announced the...
Nuvalent
Advertisement
Nuvalent Zidesamtinib Shows Strong NSCLC Trial Results
CAMBRIDGE, Mass., April 17, 2026 Nuvalent, Inc. has reported compelling clinical and preclinical data for its investigational drug zidesamtinib,...
Nuvalent Submits NDA for Neladalkib in ALK Lung Cancer
CAMBRIDGE, Mass., April 7, 2026 Nuvalent, Inc. has announced the submission of a New Drug Application (NDA) to the...
FDA Accepts NDA for Nuvalent’s Zidesamtinib in ROS1+ NSCLC
Cambridge, Massachusetts — November 19, 2025 — Nuvalent, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
Advertisement
